Abstract:To the Editor: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a potentially lethal autoimmune disease characterized by prominent psychiatric symptoms and seizures. It usually occurs in young female patients with ovarian teratomas.[1] Here, we describe a severe case of anti-NMDAR encephalitis. The patient was originally misdiagnosed as psychosis and did not improve within the first 4 weeks of first-line immunotherapy. Although she did not continue to receive second-line immunotherapy, the patient still recovered well and had no recurrence or tumor observed during 3 years of follow-up. A 17-year-old female patient was transferred from a mental health center to our hospital with psychiatric symptoms, behavioral changes, and seizures. Eleven days earlier, paranoia and behavioral changes of the patient obviously developed, followed by confusion, low-grade fever, and generalized seizures. She had no history of epilepsy or psychosis. On physical examination, the patient remained nonverbal and unresponsive to external stimulus. She demonstrated bilateral Babinski signs and no meningeal signs. Blood tests showed erythrocyte sedimentation rate 58 mm/h. Chest computed tomography suggested mild lung infection. Abdominal and pelvic color ultrasound and cranial magnetic resonance imaging were normal. Cerebrospinal fluid (CSF) analysis showed 15 nucleated cells/μL, protein of 0.40 g/L, glucose of 3.81 mmol/L, and chloride of 117.5 mmol/L. A 2-h video electroencephalogram showed nonspecific generalized slow activity without epileptic discharges. The patient was initially suspected as viral encephalitis and received intravenous (IV) acyclovir and antiepileptic drugs. She manifested oro-lingual-facial dyskinesias and hypersalivation within 1 week of admission. The latter symptom was similar to “bubbles of a crab” covering her nose and mouth. NMDAR antibodies were detected in CSF and serum 4 days after admission. We treated the patient twice with IV immunoglobulin (IVIG) 0.4 g/kg per day for 5 days at a 2-week interval and IV methylprednisolone 500 mg per day for 5 days. The seizures were under control, but the psychiatric symptoms were not improved. She had a modified Rankin Scale (mRS) score of 5 at 4 weeks after treatment. Then the patient was transferred to the rehabilitation hospital. The mRS score was 2 after 6 months. So far, the patient has been followed up for 3 years with no recurrence or tumor observed. Our patient was misdiagnosed as a psychiatric disorder at the onset of the disease. Around 80% of patients with anti-NMDAR encephalitis present initially with psychiatric symptoms.[2] Therefore, it is necessary to consider anti-NMDAR encephalitis in the differential diagnosis of patients with acute onset psychiatric symptoms.[2] Oro-lingual-facial dyskinesias and hypersalivation were impressive in this case. The former may be easily misdiagnosed as seizures and is often a clue to the diagnosis of anti-NMDAR encephalitis.[3] In particular, the latter symptom with “bubbles of a crab” covering her nose and mouth was rarely reported before.[4] Around 60% of patients with anti-NMDAR encephalitis are detected with tumors.[3] In this case, the tumor was not found during a 3-year follow-up period. However, she should continue to be followed up as ovarian teratoma may occur in patients with anti-NMDAR encephalitis through the years.[5] The patients who fail first-line immunotherapy (steroids, IVIG, plasmapheresis) within the first 4 weeks continue to have a poor prognosis and second-line immunotherapy (rituximab, cyclophosphamide) can improve the outcome of those patients.[1] Considering the potential side effects, the second-line immunotherapy was not subsequently performed in this case. In summary, the probable anti-NMDAR encephalitis should be seriously considered when the patients originally present acute psychiatric symptoms. Although some patients with anti-NMDAR encephalitis who initially fail first-line immunotherapy are not further treated with second-line immunotherapy, they may still recover well. Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her images and other clinical information to be reported in the journal. The patient understands that her name and initial will not be published and due efforts will be made to conceal her identity, but anonymity cannot be guaranteed. Conflicts of interest None.

Refractory anti-NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review

Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: An observational study

Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis

Anti-N-Methyl-D-Aspartate Receptor Encephalitis with Occult Ovarian Teratoma: A Case Report

A refractory anti-NMDA receptor encephalitis successfully treated by bilateral ovariectomy and intrathecal injection of methotrexate and dexamethasone: A case report

Anti-GABA-A Receptor Antibody-Mediated Epilepsia Partialis Continua After Treatment With Alemtuzumab: A Case Report

A critical reflection on our first patient presenting with Anti-Nmethyl- D-aspartate receptor encephalitis

Case report: Rapid recovery after intrathecal rituximab administration in refractory anti-NMDA receptor encephalitis: report of two cases

Case report: Anti- N-methyl-D-aspartate receptor antibody-associated autoimmunity triggered by primary central nervous system B-cell lymphoma

044 Dramatic delayed recovery following severe anti-NMDAR encephalitis

Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody, in the Treatment of Severe Refractory Anti-N-methyl-D-Aspartate Receptor Encephalitis: Two Case Reports

Pharmaceutical care of rituximab in the treatment of children with refractory anti-NMDAR encephalitis: A case report

Anti-NMDA Receptor Encephalitis Related to Renal Cell Carcinoma: A Case Report

Utility and Safety of Intrathecal Methotrexate Treatment in Severe Anti-N-methyl-D-aspartate Receptor Encephalitis: A Pilot Study

Clinical approach to the diagnosis and successful management of anti-NMDA receptor encephalitis when antibody testing is not possible

Extra-central nervous system target for assessment and treatment in refractory anti-N-methyl-d-aspartate receptor encephalitis

Intrathecal methotrexate – Another tool for the treatment of refractory autoimmune encephalitis - Single institution cohort and literature review

109 Severe dysautonomia in NMDAR encephalitis

Anti-NMDA encephalitis secondary to an ovarian teratoma presenting as altered mental status in a 32-year-old woman: A case report

Anti-N-methyl-D-aspartate Receptor Encephalitis in a 17-Year-old Female Patient with 3 Years of Follow-Up.

[A case report of anti-NMDA receptor encephalitis with mental disturbances manifestation]